http://www.acc.org/Feed?clinicalTopicID=07fcd7df-a463-421b-b927-d29a1be75766 Clinical Topic Feed: Anticoagulation Management and Atrial Fibrillation en /Latest-in-Cardiology/Articles/2026/07/08/14/16/eagles-eye-view-08jul2026 In this week’s View, Dr. Eagle looks at withdrawing guideline-directed medical therapy (GDMT) for patients with atrial fibrillation (AF). 1783520220000 Articles and Stories /Latest-in-Cardiology/Articles/2026/06/29/15/28/Discontinuation-of-Anticoagulation Current guidelines for management of atrial fibrillation (AF) recommend continuation of oral anticoagulation (OAC) following successful catheter ablation of AF for patients deemed at elevated thromboembolic risk. 1782921180000 Articles and Stories /Latest-in-Cardiology/Articles/2026/06/29/15/28/Poll-Results-Brainstorm This poll included a clinical vignette of an 80-year-old man with atrial fibrillation (AF), high thromboembolic risk, and multiple cardiovascular (CV) comorbidities who presented 2 months after a spontaneous lobar intracerebral hemorrhage while receiving reduced-dose apixaban... 1782913920000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/06/29/15/38/ACC-Scientific-Statement-Addresses-DOACs Even with robust evidence demonstrating their efficacy and safety, direct oral anticoagulants (DOACs) continue to be underused and, at times, inappropriately dosed, particularly in patients at elevated thrombotic risk. 1782828120000 Articles and Stories /Latest-in-Cardiology/Articles/2026/06/29/15/28/Discontinuation-of-Oral-Anticoagulation The ALONE-AF (Anticoagulation One Year After Ablation of Atrial Fibrillation in Patients With Atrial Fibrillation) trial examined whether discontinuing oral anticoagulation (OAC) in patients with elevated stroke risk after catheter ablation of atrial fibrillation (AFCA) who remain free of atrial arrhythmias in the year after their indexed ablation leads to fewer adverse clinical outcomes. 1782752820000 Articles and Stories /Latest-in-Cardiology/Articles/2026/06/22/17/39/Catheter-Based-LAAO-vs-Medical-Therapy-in-High-Risk-AF The CLOSURE-AF (Catheter-Based Left Atrial Appendage Closure in Patients With Atrial Fibrillation at High Risk of Stroke and Bleeding as Compared With Best Medical Therapy) trial found that, among patients with atrial fibrillation (AF) at high risk for both stroke and bleeding, catheter-based left atrial appendage occlusion... 1782154680000 Articles and Stories /Latest-in-Cardiology/Articles/2026/06/08/10/20/Poll-Brainstorm An 80-year-old man presents for a cardiovascular follow-up after a prolonged hospitalization in the setting of an intracerebral hemorrhage. His medical history is relevant for atrial fibrillation, stage 3b chronic kidney disease, heart failure with preserved ejection fraction, hypertension, myocardial infarction 10 years ago, and type 2 diabetes mellitus. 1780929600000 Articles and Stories /Latest-in-Cardiology/Articles/2026/05/12/15/21/eagles-eye-view-13may2026 In this week’s View, Dr. Eagle examines the role of rhythm control in improving moderate-to-severe and severe secondary tricuspid valve regurgitation. 1778679000000 Articles and Stories /Latest-in-Cardiology/Journal-Scans/2026/05/04/11/24/Continuing-vs-Switching-DOAC-Therapy In patients with atrial fibrillation (AFib) experiencing a breakthrough ischemic stroke while on a direct oral anticoagulant (DOAC) regimen, switching to a different DOAC was noninferior to continuing the same DOAC, according to a study published April 28 in JAMA Network Open. 1778074320000 Articles and Stories /Latest-in-Cardiology/Articles/2026/04/21/15/23/CHAMPION-AF The CHAMPION-AF trial randomized 3,000 patients with nonvalvular atrial fibrillation (AFib) (mean age, 72 years; mean CHA2DS2-VASc score, 3.5; mean HAS-BLED score, 1.3) who were suitable for long-term oral anticoagulation to either left atrial appendage closure (LAAC) (Watchman Flx, Boston Scientific) or non–vitamin K antagonist oral anticoagulants (NOACs). 1776939000000 Articles and Stories